190 related articles for article (PubMed ID: 29630127)
1. Research and analysis of 74 bloodstream infection cases of Acinetobacter baumannii and drug resistance.
Wu HG; Liu WS; Zhu M; Li XX
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1782-1786. PubMed ID: 29630127
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.
Munoz-Price LS; Zembower T; Penugonda S; Schreckenberger P; Lavin MA; Welbel S; Vais D; Baig M; Mohapatra S; Quinn JP; Weinstein RA
Infect Control Hosp Epidemiol; 2010 Oct; 31(10):1057-62. PubMed ID: 20715975
[TBL] [Abstract][Full Text] [Related]
3. [Multidrug-resistant Acinetobacter Baumannii infection in Intensive Care Unit: A retrospective analysis].
He L; Meng J; Huang D; Hu C; Pan P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 40(12):1327-32. PubMed ID: 26739074
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Mortality in Children with
Choe YJ; Lee HJ; Choi EH
Microb Drug Resist; 2019 Oct; 25(8):1210-1218. PubMed ID: 31120349
[No Abstract] [Full Text] [Related]
6. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
[TBL] [Abstract][Full Text] [Related]
7. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH
Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
Vandepitte WP; Berge J; Andersson R
J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
[TBL] [Abstract][Full Text] [Related]
9. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
Zhang TQ; Dong L; Wang ZY; Li HY
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
Anunnatsiri S; Tonsawan P
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of drug resistance of Acinetobacter baumannii and its related factors in ICU].
Ma MY; Xu J; Yu N; Huang GM
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Nov; 25(11):686-9. PubMed ID: 24225215
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
14. Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in
Liu Y; Wang Q; Zhao C; Chen H; Li H; Wang H; Cares Network OBOT
J Med Microbiol; 2020 Jul; 69(7):949-959. PubMed ID: 32584215
[No Abstract] [Full Text] [Related]
15. Emergence in Taiwan of novel imipenem-resistant Acinetobacter baumannii ST455 causing bloodstream infection in critical patients.
Lee HY; Huang CW; Chen CL; Wang YH; Chang CJ; Chiu CH
J Microbiol Immunol Infect; 2015 Dec; 48(6):588-96. PubMed ID: 26055692
[TBL] [Abstract][Full Text] [Related]
16. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.
Tal-Jasper R; Katz DE; Amrami N; Ravid D; Avivi D; Zaidenstein R; Lazarovitch T; Dadon M; Kaye KS; Marchaim D
Antimicrob Agents Chemother; 2016 May; 60(5):3127-31. PubMed ID: 26883694
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.
Lee YT; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Yang YS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674056
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children.
Punpanich W; Nithitamsakun N; Treeratweeraphong V; Suntarattiwong P
Int J Infect Dis; 2012 Nov; 16(11):e811-5. PubMed ID: 22898148
[TBL] [Abstract][Full Text] [Related]
20. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii.
Sheng WH; Liao CH; Lauderdale TL; Ko WC; Chen YS; Liu JW; Lau YJ; Wang LH; Liu KS; Tsai TY; Lin SY; Hsu MS; Hsu LY; Chang SC
Int J Infect Dis; 2010 Sep; 14(9):e764-9. PubMed ID: 20646946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
